A 48-year-old woman with newly diagnosed hypertension (BP 162/104 mmHg) and type 2 diabetes mellitus (HbA1c 8.2%) presents for antihypertensive therapy initiation. She has no prior cardiovascular events, normal renal function (eGFR 88 mL/min/1.73m²), and urine albumin-to-creatinine ratio (UACR) of 45 mg/g. What is the most appropriate initial antihypertensive agent?

## Clinical Context: Hypertension + Diabetes + Albuminuria This patient has three key features that guide antihypertensive selection: 1. **Type 2 diabetes mellitus** — increases cardiovascular and renal risk 2. **Microalbuminuria** (UACR 45 mg/g, normal <30 mg/g) — indicates early diabetic kidney disease 3. **Normal renal function** — eGFR 88 mL/min/1.73m² (no advanced CKD) ## Why ACE Inhibitor Is First-Line **Key Point:** ACE inhibitors (and ARBs) are the preferred first-line agents for hypertensive patients with diabetes and albuminuria because they provide: 1. **Renal protection** — reduce intraglomerular pressure via efferent arteriolar vasodilation 2. **Reduction of proteinuria/albuminuria** — slow progression of diabetic nephropathy 3. **Cardiovascular protection** — reduce MI and stroke risk in diabetes 4. **Blood pressure control** — effective BP reduction **High-Yield:** ACE-I/ARB are the ONLY antihypertensive class proven to slow the progression of diabetic kidney disease. This is a major guideline recommendation across ACC/AHA, KDIGO, and ADA. **Mnemonic:** **RAAS-I First in Diabetes** — Renin–Angiotensin–Aldosterone System Inhibitors (ACE-I, ARB, DRI) are first-line for hypertensive diabetic patients, especially with albuminuria. ## Why Other Agents Are Suboptimal ### Amlodipine (Dihydropyridine CCB) - Effective for BP control but does NOT reduce proteinuria - May cause reflex tachycardia and fluid retention - Appropriate as add-on therapy, not monotherapy in this setting ### Hydrochlorothiazide (Thiazide Diuretic) - **Warning:** Thiazides worsen glucose control and increase HbA1c in diabetic patients - May precipitate or worsen hyperglycemia - Increases uric acid and triglycerides - NOT recommended as first-line in diabetes ### Metoprolol (Beta-Blocker) - No renal protective effect - May mask hypoglycemia symptoms in diabetic patients - May worsen glucose control - Reserved for patients with CAD, post-MI, or heart failure ## Comparison Table | Agent | BP Control | Renal Protection | Glucose Effect | Albuminuria Reduction | First-Line in Diabetes? | | --- | --- | --- | --- | --- | --- | | ACE-I (Lisinopril) | ✓ Good | ✓ Excellent | Neutral/Improves | ✓ Yes | **YES** | | ARB | ✓ Good | ✓ Excellent | Neutral/Improves | ✓ Yes | **YES** | | CCB (Amlodipine) | ✓ Good | ✗ None | Neutral | ✗ No | No (add-on) | | Thiazide | ✓ Good | ✗ None | ✗ Worsens | ✗ No | **NO** | | Beta-blocker | ✓ Good | ✗ None | ✗ Worsens | ✗ No | No | ## Guideline Consensus **Clinical Pearl:** ACC/AHA 2017 Hypertension Guidelines, KDIGO 2021 CKD Guidelines, and ADA Standards of Care all recommend ACE-I or ARB as first-line antihypertensive therapy in hypertensive patients with diabetes and albuminuria/proteinuria.